CEPHALOSPORIN COMPOUND
The cephalosporin compound of formula (I) is disclosed, which exhibits antibiotic activity against Gram-negative (e.g., Pseudomonas aeruginosa ) and Gram-positive (e.g., methicillin-resistant Staphylococcus aureus ) bacteria. Methods of manufacturing the compound of formula (I), and uses of the compound in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
1 - 3 . (canceled)
4 . A method for treating an infectious disease comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising the compound of Formula (I):
or a pharmaceutically acceptable salt thereof.
5 - 9 . (canceled)
10 . The method of claim 4 , wherein the infectious diseases is caused by a Gram-negative bacteria.
11 . The method of claim 10 , wherein the Gram-negative bacteria is Pseudomonas aeruginosa.
12 . The method of claim 4 , wherein the subject has hospital acquired pneumonia (HAP).
13 . The method of claim 4 , wherein the subject has ventilator acquired pneumonia (VAP).
14 . A method of treating an infection caused by Pseudomonas aeruginosa, comprising parenterally administering to a patient in need thereof a pharmaceutical composition comprising a carrier and a therapeutically effective amount of a compound of Formula (I):
a physiologically hydrolyzable ester thereof, a solvate thereof, or a pharmacologically acceptable salt thereof.
15 . The method of claim 14 , wherein the therapeutically effective amount is effective against a Pseudomonas aeruginosa bacteria with a minimum inhibitory concentration (MIC) of not more than about 4 micrograms/mL.
16 . The method of claim 15 , wherein the minimum inhibitory concentration (MIC) is not more than about 2 micrograms/mL.
17 . The method of claim 15 , wherein the minimum inhibitory concentration (MIC) is not more than about 1 microgram/mL.
18 . The method of claim 15 , wherein the subject has hospital acquired pneumonia (HAP).
19 . The method of claim 15 , wherein the subject has ventilator acquired pneumonia (VAP).
20 . A method of making the compound of Formula (I) comprising the step of reacting intermediate compound 6:
with an intermediate compound 12:
to produce the compound of Formula (I):